Top

Published in:

01-12-2020 | Diffuse Large B-Cell Lymphoma | Original Article

Validation and comparison of prognostic values of GNRI, PNI, and CONUT in newly diagnosed diffuse large B cell lymphoma

Authors: Toshihiro Matsukawa, Keito Suto, Minoru Kanaya, Koh Izumiyama, Koichiro Minauchi, Shota Yoshida, Hisashi Oda, Takuto Miyagishima, Akio Mori, Shuichi Ota, Daigo Hashimoto, Takanori Teshima, North Japan Hematology Study Group (NJHSG)

Published in: Annals of Hematology | Issue 12/2020

Abstract

Diffuse large B cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma. Emerging evidence indicates that poor nutritional status determined with nutritional indices such as geriatric nutritional risk index (GNRI), prognostic nutritional index (PNI), and controlling nutritional status score (CONUT) was associated with poor prognosis of DLBCL. We conducted this multicenter retrospective study to validate and compare prognostic values of the three indices in 615 newly diagnosed DLBCL patients. The overall survival (OS) in patients with poor nutritional status determined with each of these nutritional indices were significantly inferior compared with that in those without nutritional risks (5-year OS in patients with GNRI < 95.7 and GNRI ≥ 95.7 were 56.4% and 83.5%, P < 0.001; PNI < 42.4 and PNI ≥ 42.4 were 56.1% and 81.0%, P < 0.001; CONUT > 4 and CONUT ≤ 4 were 53.1% and 77.1%, P < 0.001). GNRI and CONUT were independent prognostic predictors for OS (GNRI < 95.7, hazard ratio [HR] 1.83, 95% confidence interval [CI] 1.22–2.74, P = 0.0032; CONUT > 4, HR 1.53, 95% CI 1.05–2.23, P = 0.028) after multivariate analyses. Nutritional status determined with GNRI affected OS more strongly in the patients with nongerminal center B cell–like (nonGCB) DLBCL compared with that in those with GCB-type DLBCL. In conclusion, baseline poor nutritional status determined based on GNRI or CONUT was an independent risk factor of newly diagnosed DLBCL, and GNRI was also useful as an independent prognostic factor for patients with nonGCB-type DLBCL.

Available only for authorised users

Swerdlow SHCE, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele JVJ (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. France IARC Press, Lyon, France, pp 233–237

Miao Y, Medeiros LJ, Li Y, Li J, Young KH (2019) Genetic alterations and their clinical implications in DLBCL. Nat Rev Clin Oncol 16(10):634–652. https://doi.org/10.1038/s41571-019-0225-1CrossRefPubMed

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346(4):235–242. https://doi.org/10.1056/NEJMoa011795CrossRefPubMed

Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, Stahel R, Kvaloy S, Shpilberg O, Jaeger U, Hansen M, Lehtinen T, Lopez-Guillermo A, Corrado C, Scheliga A, Milpied N, Mendila M, Rashford M, Kuhnt E, Loeffler M, MabThera International Trial G (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7(5):379–391. https://doi.org/10.1016/S1470-2045(06)70664-7CrossRefPubMed

International Non-Hodgkin’s Lymphoma Prognostic Factors P (1993) A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 329(14):987–994. https://doi.org/10.1056/NEJM199309303291402CrossRef

Sonnen R, Schmidt WP, Kuse R, Schmitz N (2002) Treatment results of aggressive B non-Hodgkin’s lymphoma in advanced age considering comorbidity. Br J Haematol 119(3):634–639. https://doi.org/10.1046/j.1365-2141.2002.03896.xCrossRefPubMed

Advani RH, Chen H, Habermann TM, Morrison VA, Weller EA, Fisher RI, Peterson BA, Gascoyne RD, Horning SJ, Eastern Cooperative Oncology G, Cancer, Leukemia Group B, Southwest Oncology G (2010) Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic index (E-IPI). Br J Haematol 151(2):143–151. https://doi.org/10.1111/j.1365-2141.2010.08331.xCrossRefPubMedPubMedCentral

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, Klasa R, Savage KJ, Shenkier T, Sutherland J, Gascoyne RD, Connors JM (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109(5):1857–1861. https://doi.org/10.1182/blood-2006-08-038257CrossRefPubMed

Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN (2014) An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123(6):837–842. https://doi.org/10.1182/blood-2013-09-524108CrossRefPubMedPubMedCentral

10.

Park S, Han B, Cho JW, Woo SY, Kim S, Kim SJ, Kim WS (2014) Effect of nutritional status on survival outcome of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. Nutr Cancer 66(2):225–233. https://doi.org/10.1080/01635581.2014.867065CrossRefPubMed

11.

Bairey O, Shacham-Abulafia A, Shpilberg O, Gurion R (2016) Serum albumin level at diagnosis of diffuse large B-cell lymphoma: an important simple prognostic factor. Hematol Oncol 34(4):184–192. https://doi.org/10.1002/hon.2233CrossRefPubMed

12.

Cox MC, Nofroni I, Ruco L, Amodeo R, Ferrari A, La Verde G, Cardelli P, Montefusco E, Conte E, Monarca B, Aloe-Spiriti MA (2008) Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma. Leuk Lymphoma 49(9):1745–1751. https://doi.org/10.1080/10428190802226425CrossRefPubMed

13.

Cox MC, Nofroni I, Laverde G, Ferrari A, Amodeo R, Tatarelli C, Saltarelli F, Veggia B, Aloe-Spiriti MA, Ruco L, Monarca B (2008) Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma. Br J Haematol 141(2):265–268. https://doi.org/10.1111/j.1365-2141.2008.07028.xCrossRefPubMed

14.

Gao R, Liang JH, Wang L, Zhu HY, Wu W, Cao L, Fan L, Li JY, Yang T, Xu W (2018) Low serum cholesterol levels predict inferior prognosis and improve NCCN-IPI scoring in diffuse large B cell lymphoma. Int J Cancer 143(8):1884–1895. https://doi.org/10.1002/ijc.31590CrossRefPubMed

15.

Kanemasa Y, Shimoyama T, Sasaki Y, Hishima T, Omuro Y (2018) Geriatric nutritional risk index as a prognostic factor in patients with diffuse large B cell lymphoma. Ann Hematol 97(6):999–1007. https://doi.org/10.1007/s00277-018-3273-1CrossRefPubMed

16.

Li Z, Guo Q, Wei J, Jin J, Wang J (2018) Geriatric nutritional risk index is not an independent predictor in patients with diffuse large B-cell lymphoma. Cancer Biomark 21(4):813–820. https://doi.org/10.3233/CBM-170754CrossRefPubMed

17.

Go SI, Park S, Kang MH, Kim HG, Kim HR, Lee GW (2019) Clinical impact of prognostic nutritional index in diffuse large B cell lymphoma. Ann Hematol 98(2):401–411. https://doi.org/10.1007/s00277-018-3540-1CrossRefPubMed

18.

Lee S, Fujita K, Morishita T, Negoro E, Oiwa K, Tsukasaki H, Yamamura O, Ueda T, Yamauchi T (2020) Prognostic utility of a geriatric nutritional risk index in combination with a comorbidity index in elderly patients with diffuse large B cell lymphoma. Br J Haematol. https://doi.org/10.1111/bjh.16743

19.

Hamada E, Shinji O, Nishiyama-Fujita Y, Akiimoto M, Tanigawa T, Ito C, Sakurai A, Aisa Y, Nakazato T (2020) The clinical significance of the prognostic nutritional index in very elderly patients over 80 years of age with diffuse large B-cell lymphoma. Ann Hematol 99(5):1153–1155. https://doi.org/10.1007/s00277-020-04012-7CrossRefPubMed

20.

Nagata A, Kanemasa Y, Sasaki Y, Nakamura S, Okuya T, Funasaka C, Kageyama A, Shimoyama T, Omuro Y (2020) Clinical impact of Controlling Nutritional Status (CONUT) score on the prognosis of patients with diffuse large B-cell lymphoma. Hematol Oncol 38:309–317. https://doi.org/10.1002/hon.2732CrossRefPubMed

21.

Ignacio de Ulibarri J, Gonzalez-Madrono A, de Villar NG, Gonzalez P, Gonzalez B, Mancha A, Rodriguez F, Fernandez G (2005) CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp 20(1):38–45PubMed

22.

Onodera T, Goseki N, Kosaki G (1984) Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi 85(9):1001–1005PubMed

23.

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275–282. https://doi.org/10.1182/blood-2003-05-1545CrossRefPubMed

24.

Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, Benazeth S, Cynober L, Aussel C (2005) Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr 82(4):777–783. https://doi.org/10.1093/ajcn/82.4.777CrossRefPubMed

25.

Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48(3):452–458. https://doi.org/10.1038/bmt.2012.244CrossRefPubMed

26.

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr, Lu L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769):503–511. https://doi.org/10.1038/35000501CrossRefPubMed

27.

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T, Staudt LM, Lymphoma/Leukemia Molecular Profiling P (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346 (25):1937-1947. https://doi.org/10.1056/NEJMoa012914

28.

Zhou Q, Wei Y, Huang F, Wei X, Wei Q, Hao X, Zhang Y, Feng R (2016) Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP. Int J Hematol 104(4):485–490. https://doi.org/10.1007/s12185-016-2052-9CrossRefPubMed

29.

Arroyo V, Garcia-Martinez R, Salvatella X (2014) Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol 61(2):396–407. https://doi.org/10.1016/j.jhep.2014.04.012CrossRefPubMed

30.

Sugino H, Hashimoto I, Tanaka Y, Ishida S, Abe Y, Nakanishi H (2014) Relation between the serum albumin level and nutrition supply in patients with pressure ulcers: retrospective study in an acute care setting. J Med Investig 61(1-2):15–21. https://doi.org/10.2152/jmi.61.15CrossRef

31.

Karas PL, Goh SL, Dhital K (2015) Is low serum albumin associated with postoperative complications in patients undergoing cardiac surgery? Interact Cardiovasc Thorac Surg 21(6):777–786. https://doi.org/10.1093/icvts/ivv247CrossRefPubMed

32.

Gupta D, Lis CG (2010) Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 9:69. https://doi.org/10.1186/1475-2891-9-69CrossRefPubMedPubMedCentral

33.

Williams JP, Phillips BE, Smith K, Atherton PJ, Rankin D, Selby AL, Liptrot S, Lund J, Larvin M, Rennie MJ (2012) Effect of tumor burden and subsequent surgical resection on skeletal muscle mass and protein turnover in colorectal cancer patients. Am J Clin Nutr 96(5):1064–1070. https://doi.org/10.3945/ajcn.112.045708CrossRefPubMed

34.

Alshadwi A, Nadershah M, Carlson ER, Young LS, Burke PA, Daley BJ (2013) Nutritional considerations for head and neck cancer patients: a review of the literature. J Oral Maxillofac Surg 71(11):1853–1860. https://doi.org/10.1016/j.joms.2013.04.028CrossRefPubMed

35.

Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489–495. https://doi.org/10.1016/S1470-2045(10)70218-7CrossRefPubMed

36.

Davis RE, Brown KD, Siebenlist U, Staudt LM (2001) Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 194(12):1861–1874. https://doi.org/10.1084/jem.194.12.1861CrossRefPubMedPubMedCentral

37.

Lam LT, Davis RE, Ngo VN, Lenz G, Wright G, Xu W, Zhao H, Yu X, Dang L, Staudt LM (2008) Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen. Proc Natl Acad Sci U S A 105(52):20798–20803. https://doi.org/10.1073/pnas.0806491106CrossRefPubMedPubMedCentral

38.

Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, Zhang Y, Cattoretti G, Ye BH (2008) Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111(3):1515–1523. https://doi.org/10.1182/blood-2007-04-087734CrossRefPubMedPubMedCentral

39.

Fearon KC, Von Meyenfeldt MF, Moses AG, Van Geenen R, Roy A, Gouma DJ, Giacosa A, Van Gossum A, Bauer J, Barber MD, Aaronson NK, Voss AC, Tisdale MJ (2003) Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 52(10):1479–1486. https://doi.org/10.1136/gut.52.10.1479CrossRefPubMedPubMedCentral

Title: Validation and comparison of prognostic values of GNRI, PNI, and CONUT in newly diagnosed diffuse large B cell lymphoma
Authors: Toshihiro Matsukawa
Keito Suto
Minoru Kanaya
Koh Izumiyama
Koichiro Minauchi
Shota Yoshida
Hisashi Oda
Takuto Miyagishima
Akio Mori
Shuichi Ota
Daigo Hashimoto
Takanori Teshima
North Japan Hematology Study Group (NJHSG)
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keywords: Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma
Published in: Annals of Hematology / Issue 12/2020
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-020-04262-5

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2020

Early-stage mantle cell lymphoma—a rare entity with special characteristics and needs for treatment

Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting

Pediatric recurrent Rosai-Dorfman disease with germline heterozygous SLC29A3 and somatic MAP2K1 mutations

KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients

Reevaluation of reference values for bone marrow differential counts in 236 healthy bone marrow donors

Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage